DRUG STUDY: NCM 106 PHARMACOLOGY Instructor: _______________________________________ Date: ________________________
NAME: ____________________________________________________________ BLOCK and Year:___________________________Group: ______________________________
DRUG NAME MECHANISM OF INDICATION CONTRAINDICATION ADVERSE EFFECTS NURSING INTERVENTIONS
ACTION Generic Name: Exerts antiviral effect CMV retinitis in AIDS Hypersensitivity to drug, CNS: headache, seizures, Patient monitoring: cidofovir by interfering with patients probenecid, or other sulfa- coma Assess white blood cell DNA synthesis of containing agents EENT: decreased count and creatinine and CMV, thereby Creatininelevelabove1.5mg/ intraocular pressure urine protein levels inhibiting viral dl, calculated creatinine GI: nausea, vomiting, within 48 hours of each replication diarrhea, anorexia, oral dose. clearance of 55 ml/ minute candidiasis Drug Classification: or less, or urine protein Closely monitor GU: proteinuria, Antiviral level of 100 mg/dl or higher nephrotoxicity intraocular pressure and Concurrent use of Hematologic: neutropenia visual acuity. nephrotoxic drugs Hepatic: hepatomegaly Monitor hepatic enzyme Metabolic: metabolic levels in patients with acidosis hepatic disease. Musculoskeletal: muscle contractions Patient teaching: Available Dosage: Respiratory: dyspnea, Tell patient to CMV retinitis in increased cough immediately report AIDS patients Skin: rash, alopecia fever, vision Adults: 5 mg/kg I.V. Other: pain, fever, chills, changes, nausea, infused over 1 hour infection, pain at I.V. site vomiting, rash, or q week for 2 urinary output continuous weeks; changes. then 5 mg/kg I.V. Instruct patient to once q 2 weeks as a take probenecid, as maintenance dose prescribed, before each dose and to have regular eye examinations. Urge female patient of childbearing age to use effective contraception during and for 1 month after therapy. Instruct male patients to use barrier contraception during and for 3 months after therapy. As appropriate, review all other significant and life- threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.